Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-11-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于首次实施回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's first implementation of a share repurchase plan. It details the board meeting approval, the amount and price limits for the buyback, the actual shares repurchased on November 1, 2023, and compliance with regulatory guidelines. The text focuses on the share repurchase activity and related disclosures, without containing financial statements or broader financial performance data. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2023-11-01 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购报告书" which translates to "Repurchase Report" or "Share Buyback Report." It details the company's plan to repurchase its own shares using self-owned funds, including the purpose, amount, price limits, implementation period, and regulatory compliance. It also includes risk disclosures, board approvals, and information about the shareholding structure before and after the repurchase. The document is 8568 characters long, which is substantial and contains detailed information about the share repurchase plan, not just an announcement of the plan or a brief summary. This matches the description of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. There is no indication that this is a simple announcement or a regulatory filing of a different nature. Therefore, the correct classification is POS with high confidence.
2023-10-30 Chinese
关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the top 10 shareholders and top 10 unrestricted shareholders of the company prior to a share repurchase plan. It references a previous announcement about the share repurchase plan and provides detailed shareholding information as of a specific date. The content focuses on shareholding changes related to a share buyback, which fits the category of a Transaction in Own Shares (POS). The document length is short and it is not a full financial report or regulatory filing but a specific announcement about share repurchase and shareholder holdings.
2023-10-30 Chinese
第五届董事会第二十一次临时会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement of the resolutions passed at a board meeting of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It includes approval of the 2023 Q3 report, a work summary and plan for the audit committee, and most notably, a detailed plan for the company to repurchase its own shares through centralized bidding. The document includes specifics on the purpose, conditions, price range, quantity, funding source, implementation period, and authorization for the share repurchase. It is not the actual financial report (Q3 report) itself but a board resolution announcement related to share repurchase and other governance matters. The document length is 3547 characters, which is relatively short and focused on the board meeting resolutions and share repurchase plan. This fits best under the category of Transaction in Own Shares (POS), which covers announcements of company buying back its own shares. The document is not a full financial report, earnings release, or regulatory filing, but a formal announcement of a share repurchase plan approved by the board.
2023-10-27 Chinese
关于以集中竞价交易方式回购公司股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from a company regarding a share repurchase plan using centralized bidding. It details the purpose, amount, price, quantity, duration, risks, and regulatory compliance of the share buyback. It also includes management analysis on the impact of the buyback and disclosures about insider trading and shareholding changes. The document is not a financial report, earnings release, or management discussion but a formal notification about the company's intention and plan to repurchase its own shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements of share repurchases or buybacks.
2023-10-27 Chinese
第五届监事会第十六次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the approval of the company's 2023 third quarter report. It references the actual 2023 third quarter report published separately on the cninfo website (announcement 2023-076). The document itself does not contain the financial data or substantive analysis of the quarterly report but only the Supervisory Board's approval and confirmation of the report's compliance and accuracy. The document length is short (753 characters) and serves as an announcement of the meeting resolution and approval, not the report itself. According to the 'Menu vs Meal' rule, this is a Regulatory Filing (RNS) because it is an announcement related to a report, not the report itself.
2023-10-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.